These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

388 related articles for article (PubMed ID: 34351214)

  • 1. Cost-effectiveness analysis of cemiplimab vs pembrolizumab for treatment of advanced cutaneous squamous cell carcinoma.
    Paul E; Konidaris G; Cope S; Chen CI; Keeping S; Xu Y; Atsou K; Ayers D; Guyot P; Sasane M; Mojebi A; Kuznik A
    J Manag Care Spec Pharm; 2021 Nov; 27(11):1513-1525. PubMed ID: 34351214
    [No Abstract]   [Full Text] [Related]  

  • 2. Assessing the Value of Cemiplimab for Adults With Advanced Cutaneous Squamous Cell Carcinoma: A Cost-Effectiveness Analysis.
    Konidaris G; Paul E; Kuznik A; Keeping S; Chen CI; Sasane M; Xu Y; Atsou K; Ayers D; Ruiz ES; Khushalani NI; Cope S
    Value Health; 2021 Mar; 24(3):377-387. PubMed ID: 33641772
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-Effectiveness of Cemiplimab Versus Standard of Care in the United States for First-Line Treatment of Advanced Non-small Cell Lung Cancer With Programmed Death-Ligand 1 Expression ≥50.
    Kuznik A; Smare C; Chen CI; Venkatachalam M; Keeping S; Atsou K; Xu Y; Wilson F; Guyot P; Chan K; Glowienka E; Konidaris G
    Value Health; 2022 Feb; 25(2):203-214. PubMed ID: 35094793
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-Effectiveness of Pembrolizumab Versus Ipilimumab in Ipilimumab-Naïve Patients with Advanced Melanoma in the United States.
    Wang J; Chmielowski B; Pellissier J; Xu R; Stevinson K; Liu FX
    J Manag Care Spec Pharm; 2017 Feb; 23(2):184-194. PubMed ID: 28125365
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness analysis of pembrolizumab monotherapy versus chemotherapy for previously untreated advanced non-small cell lung cancer.
    Aziz MIA; Tan LE; Tan WHG; Toh CK; Loke LPY; Pearce F; Ng K
    J Med Econ; 2020 Sep; 23(9):952-960. PubMed ID: 32462958
    [No Abstract]   [Full Text] [Related]  

  • 6. Cost-effectiveness of Pembrolizumab as Second-line Therapy for the Treatment of Locally Advanced or Metastatic Urothelial Carcinoma in Sweden.
    Srivastava T; Prabhu VS; Li H; Xu R; Zarabi N; Zhong Y; Pellissier JM; Perini RF; de Wit R; Mamtani R
    Eur Urol Oncol; 2020 Oct; 3(5):663-670. PubMed ID: 31412001
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The cost effectiveness of pembrolizumab versus chemotherapy or atezolizumab as second-line therapy for advanced urothelial carcinoma in the United States.
    Slater RL; Lai Y; Zhong Y; Li H; Meng Y; Moreno BH; Godwin JL; Frenkl T; Sonpavde GP; Mamtani R
    J Med Econ; 2020 Sep; 23(9):967-977. PubMed ID: 32412387
    [No Abstract]   [Full Text] [Related]  

  • 8. Nivolumab vs Pembrolizumab for Treatment of US Patients With Platinum-Refractory Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Network Meta-analysis and Cost-effectiveness Analysis.
    Pei R; Shi Y; Lv S; Dai T; Zhang F; Liu S; Wu B
    JAMA Netw Open; 2021 May; 4(5):e218065. PubMed ID: 33956130
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost effectiveness of pembrolizumab vs chemotherapy as first-line treatment for metastatic NSCLC that expresses high levels of PD-L1 in Switzerland.
    Bhadhuri A; Insinga R; Guggisberg P; Panje C; Schwenkglenks M
    Swiss Med Wkly; 2019 Dec; 149():w20170. PubMed ID: 31880807
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pembrolizumab vs cemiplimab for the treatment of advanced non-small cell lung cancer with PD-L1 expression levels of at least 50%: A network meta-analysis and cost-effectiveness analysis.
    Li Y; Liang X; Yang T; Guo S; Chen X
    Front Oncol; 2022; 12():878054. PubMed ID: 36226060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of pembrolizumab for the adjuvant treatment of resected high-risk stage III melanoma in the United States.
    Bensimon AG; Zhou ZY; Jenkins M; Song Y; Gao W; Signorovitch J; Krepler C; Liu FX; Wang J; Aguiar-Ibáñez R
    J Med Econ; 2019 Oct; 22(10):981-993. PubMed ID: 31012765
    [No Abstract]   [Full Text] [Related]  

  • 12. Cost-effectiveness of Pembrolizumab Plus Axitinib Vs Nivolumab Plus Ipilimumab as First-Line Treatment of Advanced Renal Cell Carcinoma in the US.
    Watson TR; Gao X; Reynolds KL; Kong CY
    JAMA Netw Open; 2020 Oct; 3(10):e2016144. PubMed ID: 33052401
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of Pembrolizumab in Second-line Advanced Bladder Cancer.
    Sarfaty M; Hall PS; Chan KKW; Virik K; Leshno M; Gordon N; Moore A; Neiman V; Rosenbaum E; Goldstein DA
    Eur Urol; 2018 Jul; 74(1):57-62. PubMed ID: 29576265
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pembrolizumab for Previously Treated Advanced or Metastatic Urothelial Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Gallacher D; Armoiry X; Auguste P; Court R; Mantopoulos T; Patterson J; De Santis M; Cresswell J; Mistry H
    Pharmacoeconomics; 2019 Jan; 37(1):19-27. PubMed ID: 30030817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (>50%) metastatic squamous and non-squamous non-small cell lung cancer in France.
    Chouaid C; Bensimon L; Clay E; Millier A; Levy-Bachelot L; Huang M; Levy P
    Lung Cancer; 2019 Jan; 127():44-52. PubMed ID: 30642550
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness analysis of pembrolizumab for treatment of US patients with persistent, recurrent, or metastatic cervical cancer.
    Shi Y; Chen J; Shi B; Liu A
    Gynecol Oncol; 2022 Feb; 164(2):379-385. PubMed ID: 34920886
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of Pembrolizumab for Patients with Advanced, Unresectable, or Metastatic Urothelial Cancer Ineligible for Cisplatin-based Therapy.
    Patterson K; Prabhu V; Xu R; Li H; Meng Y; Zarabi N; Zhong Y; Batteson R; Pellissier J; Keefe S; Grivas P; de Wit R
    Eur Urol Oncol; 2019 Sep; 2(5):565-571. PubMed ID: 31412011
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost Effectiveness of Pembrolizumab vs. Standard-of-Care Chemotherapy as First-Line Treatment for Metastatic NSCLC that Expresses High Levels of PD-L1 in the United States.
    Huang M; Lou Y; Pellissier J; Burke T; Liu FX; Xu R; Velcheti V
    Pharmacoeconomics; 2017 Aug; 35(8):831-844. PubMed ID: 28620848
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment in locally advanced or metastatic non-small cell lung cancer with PD-L1 tumor proportion score 1% or greater.
    She L; Hu H; Liao M; Xia X; Shi Y; Yao L; Ding D; Zhu Y; Zeng S; Shen L; Huang J; Carbone DP
    Lung Cancer; 2019 Dec; 138():88-94. PubMed ID: 31655368
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CASE (CemiplimAb-rwlc Survivorship and Epidemiology) study in advanced cutaneous squamous cell carcinoma.
    Migden MR; Chandra S; Rabinowits G; Chen CI; Desai J; Seluzhytsky A; Sasane M; Campanelli B; Chen Z; Freeman ML; Ibrahim SF; Khushalani NI; Andria M; Ruiz E
    Future Oncol; 2020 Feb; 16(4):11-19. PubMed ID: 31951149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.